Intraparotid Injection of Botulinum Toxin A as a Treatment to Control Sialorrhea in Children with Cerebral Palsy

American Journal of Physical Medicine and Rehabilitation

Volumn 83, Issue 4, 2004, Pages 304-313+336

  Savarese, Robert ^a,b   Diamond, Martin ^a,b   Elovic, Elie ^a   Millis, Scott R ^c  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b CHILDREN S SPECIALIZED HOSPITAL   (United States)

^c KESSLER FOUNDATION   (United States)

Author keywords

BOTOX; Botulinum Toxin A; Cerebral Palsy; Drooling; Parotid; Salivary Gland; Sialorrhea

Indexed keywords

BOTULINUM TOXIN A;

ADULT; CEREBRAL PALSY; CHILD; CLINICAL ARTICLE; CONTINUING EDUCATION; CONTROLLED STUDY; DRUG ADMINISTRATION ROUTE; DRUG EFFICACY; DRUG SAFETY; HANDICAPPED CHILD; HUMAN; HYPERSALIVATION; INJECTION SITE; INTRAPAROTID DRUG ADMINISTRATION; PAROTID GLAND; REVIEW; SALIVARY GLAND; SIDE EFFECT; TREATMENT OUTCOME;

ADOLESCENT; BOTULINUM TOXIN TYPE A; CEREBRAL PALSY; CHILD; CHILD, PRESCHOOL; HUMANS; INJECTIONS; NEUROMUSCULAR AGENTS; PAROTID GLAND; PROSPECTIVE STUDIES; SALIVA; SIALORRHEA; TREATMENT OUTCOME;

EID: 1642385859     PISSN: 08949115     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.PHM.0000104680.28335.B9     Document Type: Review

References (68)

1. Wilkinson JA: Side effects of transdermal scopolamine. J Emerg Med 1987;5:389-92
2. Crysdale WS, Greenberg J, Koheil R, et al: The drooling patient: Team evaluation and management. Int J Pediatr Otorhinolaryngol 1985;9:241-8
3. Arnold HG, Gross CW: Transtympanic neurectomy: A solution to drooling problems. Dev Med Child Neurol 1977;19:509-13
4. Davis MJ: Parotid salivary secretion and composition in cerebral palsy. J Dent Res 1979;58:1808
5. Ekedahl C, Mansson I, Sandberg N: Swallowing dysfunction in the brain-damaged with drooling. Acta Otolaryngol 1974;78:141-9
6. Sochaniwskyj AE, Koheil RM, Bablich K, et al: Oral motor functioning, frequency of swallowing and drooling in normal children and in children with cerebral palsy. Arch Phys Med Rehabil 1986;67:866-74
7. Van De Heyning PH, Marquet JF, Creten WL: Drooling in children with cerebral palsy. Acta Otorhinolaryngol Belg 1980;34:691-705
8. Makhani JS: Dribbling of saliva in children with cerebral palsy and its management. Indian J Pediatr 1974;41:272-7
9. Harris SR, Purdy AH: Drooling and its management in cerebral palsy. Dev Med Child Neurol 1987;29:807-11
10. Garber NB: Operant procedures to eliminate drooling behavior in a cerebral palsied adolescent. Dev Med Child Neurol 1971;13:641-4
11. Rapp D: Drool control: Long-term follow-up. Dev Med Child Neurol 1980;22:448-53
12. McCracken A: Drool control and tongue thrust therapy for the mentally retarded. Am J Occup Ther 1978;32:79-85
13. Ray SA, Bundy AC, Nelson DL: Decreasing drooling through techniques to facilitate mouth closure. Am J Occup Ther 1983;37:749-53
14. Harris MM, Dignam PF: A non-surgical method of reducing drooling in cerebral-palsied children. Dev Med Child Neurol 1980;22:293-9
15. Blasco PA, Stansbury JC: Glycopyrrolate treatment of chronic drooling. Arch Pediatr Adolesc Med 1996;150:932-5
16. Camp-Bruno JA, Winsberg BG, Green-Parsons AR, et al: Efficacy of benztropine therapy for drooling. Dev Med Child Neurol 1989;31:309-19
17. Lewis DW, Fontana C, Mehallick LK, et al: Transdermal scopolamine for reduction of drooling in developmentally delayed children. Dev Med Child Neurol 1994;36:484-6
18. Rogawski MA: Transdermal scopolamine and sialorrhea. Arch Neurol 1984;41:15
19. Dworkin JP, Nadal JC: Nonsurgical treatment of drooling in a patient with closed head injury and severe dysarthria. Dysphagia 1991;6:40-9
20. Comley C, Galletly C, Ash D: Use of atropine eye drops for clozapine induced hypersalivation. Aust N Z J Psychiatry 2000;34:1033-4
21. Brodtkorb E, Wyzocka-Bakowska MM, Lillevold PE, et al: Transdermal scopolamine in drooling. J Ment Defic Res 1988;32(Pt 3):233-7
22. Goode RL, Smith RA: The surgical management of sialorrhea. Laryngoscope 1970;80:1078-89
23. Gross CW, Lazar RH: Complications on otolaryngology, in Johns ME (ed): Head and Neck Surgery, Volume 1. Burlington, Canada, BC Decker, 1986, pp 41-6
24. Siegel LK, Klingbeil MA: Control of drooling with transdermal scopolamine in a child with cerebral palsy. Dev Med Child Neurol 1991;33:1013-4
25. Duvoisin R, Yahr MD: V. A. Drills in Pharmacology and Medicine. New York, McGraw Hill, 2001, pp 318-23
26. Bachrach SJ, Walter RS, Trzcinski K: Use of glycopyrrolate and other anticholinergic medications for sialorrhea in children with cerebral palsy. Clin Pediatr (Phila) 1998;37:485-90
27. Stern LM: Preliminary study of glycopyrrolate in the management of drooling. J Paediatr Child Health 1997;33:52-4
28. Wilkie TF: The problem of drooling in cerebral palsy: A surgical approach. Can J Surg 1967;10:60-7
29. Wilkie TF, Brody GS: The surgical treatment of drooling: A ten-year review. Plast Reconstr Surg 1977;59:791-7
30. O'Dwyer TP, Timon C, Walsh MA: Surgical management of drooling in the neurologically damaged child. J Laryngol Otol 1989;103:750-2
31. Glass LW, Nobel GL, Vecchione TR: Treatment of uncontrolled drooling by bilateral excision of submaxillary glands and parotid duct ligations. Plast Reconstr Surg 1978;62:523-6
32. Dundas DF, Peterson RA: Surgical treatment of drooling by bilateral parotid duct ligation and submandibular gland resection. Plast Reconstr Surg 1979;64:47-51
33. Crysdale WS: The drooling patient: Evaluation and current surgical options. Laryngoscope 1980;90:775-83
34. Giess R, Naumann M, Werner E, et al: Injections of botulinum toxin A into the salivary glands improve sialorrhoea in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2000;69:121-3
35. Pal PK, Calne DB, Calne S, et al: Botulinum toxin A as treatment for drooling saliva in PD. Neurology 2000;54:244-7
36. Consensus conference: Clinical use of botulinum toxin. National Institutes of Health. Conn Med 1991;55:471-7
37. Botulinum-A toxin for treatment of chronic spasticity (Executive Summary File-vol. 11, no. 6, 1996). Tecnologica 1996;7-9
38. BOTOX package insert. Irvine, CA, Allergan, 1998
39. Ade-Hall RA, Moore AP: Botulinum toxin type A in the treatment of lower limb spasticity in cerebral palsy. Cochrane Database Syst Rev 2000; CD001408
40. Arens LJ, Leary PM, Goldschmidt RB: Experience with botulinum toxin in the treatment of cerebral palsy. S Afr Med J 1997;87:1001-3
41. Bakheit AM, Thilmann AF, Ward AB, et al: A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke. Stroke 2000;31:2402-6
42. Brashear A, Gordon MF, Elovic E, et al: Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med 2002;347:395-400
43. Comella CL, Jankovic J, Brin MF: Use of botulinum toxin type A in the treatment of cervical dystonia. Neurology 2000;55:S15-S21
44. Dykstra DD, Sidi AA: Treatment of detrusor-sphincter dyssynergia with botulinum A toxin: A double-blind study. Arch Phys Med Rehabil 1990;71:24-6
45. Fehlings D, Rang M, Glazier J, et al: An evaluation of botulinum-A toxin injections to improve upper extremity function in children with hemiplegic cerebral palsy [see comments]. J Pediatr 2000;137:331-7
46. Friedman A, Diamond M, Johnston MV, et al: Effects of botulinum toxin A on upper limb spasticity in children with cerebral palsy. Am J Phys Med Rehabil 2000;79:53-9
47. Glenn MB, Elovic E: Chemical denervation for the treatment of hypertonia and related disorders: Phenol and botulinum toxin. J Head Trauma Rehabil 1997;12:40-62
48. Graham HK, Aoki KR, Autti-Ramo I, et al: Recommendations for the use of botulinum toxin type A in the management of cerebral palsy. Gait Posture 2000;11:67-79
49. Grazko MA, Polo KB, Jabbari B: Botulinum toxin A for spasticity, muscle spasms, and rigidity. Neurology 1995;45:712-7
50. Hesse S, Lucke D, Malezic M, et al: Botulinum toxin treatment for lower limb extensor spasticity in chronic hemiparetic patients. J Neurol Neurosurg Psychiatry 1994;57:1321-4
51. Jankovic J: Botulinum toxin in movement disorders. Curr Opin Neurol 1994;7:358-66
52. Koman LA, Mooney JF III, Smith BP, et al: Management of spasticity in cerebral palsy with botulinum-A toxin: Report of a preliminary, randomized, double-blind trial. J Pediatr Orthop 1994;14:299-303
53. Simpson DM, Alexander DN, O'Brien CF, et al: Botulinum toxin type A in the treatment of upper extremity spasticity: A randomized, double-blind, placebo-controlled trial. Neurology 1996;46:1306-10
54. Snow BJ, Tsui JK, Bhatt MH, et al: Treatment of spasticity with botulinum toxin: A double-blind study [see comments]. Ann Neurol 1990;28:512-5
55. Wong V: Use of botulinum toxin injection in 17 children with spastic cerebral palsy. Pediatr Neurol 1998;18:124-31
56. Bushara KO: Sialorrhea in amyotrophic lateral sclerosis: A hypothesis of a new treatment. Botulinum toxin A injections of the parotid glands. Med Hypotheses 1997;48:337-9
57. Bhatia KP, Munchau A, Brown P: Botulinum toxin is a useful treatment in excessive drooling in saliva. J Neurol Neurosurg Psychiatry 1999;67:697
58. Ekstrom J, Kemplay SK, Garrett JR, et al: Effect of botulinum toxin on the choline acetyltransferase activity in salivary glands of cats. Experientia 1977;33:1458-60
59. Ellies M, Laskawi R, Gotz W, et al: Immunohistochemical and morphometric investigations of the influence of botulinum toxin on the submandibular gland of the rat. Eur Arch Otorhinolaryngol 1999;256:148-52
60. Jost WH: Treatment of drooling in Parkinson's disease with botulinum toxin. Mov Disord 1999;14:1057
61. Shaari CM, Wu BL, Biller HF, et al: Botulinum toxin decreases salivation from canine submandibular glands. Otolaryngol Head Neck Surg 1998;118:452-7
62. Vargas H, Galati LT, Parnes SM: A pilot study evaluating the treatment of postparotidectomy sialoceles with botulinum toxin type A. Arch Otolaryngol Head Neck Surg 2000;126:421-4
63. Bjerkhoel A, Trobbe O: Frey's syndrome: Treatment with botulinum toxin. J Laryngol Otol 1997;111:839-44
64. Laccourreye O, Akl E, Gutierrez-Fonseca R, et al: Recurrent gustatory sweating (Frey syndrome) after intracutaneous injection of botulinum toxin type A: Incidence, management, and outcome. Arch Otolaryngol Head Neck Surg 1999;125:283-6
65. Laskawi R, Drobik C, Schonebeck C: Up-to-date report of botulinum toxin type A treatment in patients with gustatory sweating (Frey's syndrome). Laryngoscope 1998;108:381-4
66. Mann AC: Localised autonomic failure due to botulinum toxin injection. J Neurol Neurosurg Psychiatry 1994;57:1320
67. Olney RK, Aminoff MJ, Gelb DJ, et al: Neuromuscular effects distant from the site of botulinum neurotoxin injection. Neurology 1988;38:1780-3
68. Suskind DL, Tilton AT: Clinical study of botulinum-A toxin in the treatment of sialorrhea in children with cerebral palsy. Laryngoscope 2002;112:73-81